Company Profile

Linnaeus Therapeutics LLC
Profile last edited on: 3/1/2023      CAGE: 7P7B9      UEI:

Business Identifier: Firm granted Orphan Drug Designation for LNS8801 - the firm's treatment of patients with metastatic cutaneous melanoma
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

30 Washington Avenue Suite F
Haddonfield, NJ 08033
   (856) 433-1300
Location: Single
Congr. District: 01
County: Camden

Public Profile

Linnaeus Therapeutics, Inc. (Linnaeus) is a privately held clinical-stage biopharmaceutical company focused on development and commercialization of novel small-molecule oncology therapeutics. In January 2023 it was announced that the US Food and Drug Administration (FDA) had granted orphan drug designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma. The FDA’s Office of Orphan Drug Products grants orphan drug status to support drug candidates in development for underserved patient populations or rare disorders that affect fewer than 200,000 people in the United States. Orphan drug designation provides certain benefits, including market exclusivity upon FDA approval, exemption of FDA application fees, and tax credits for qualified clinical trials. Having completed dose escalation, Linnaeus is currently testing LNS8801 in its phase 1/2 adaptive-design clinical trial as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in various cancers and patient populations.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $4,299,998
Project Title: Development of GPER Agonists as Cancer Therapeutics

Key People / Management

  Patrick T Mooney -- Chief Executive Officer

  Tina Garyantes -- Senior Vice President Research and Development

  Christopher Natale -- Cofounder & CSO

  Todd W Ridky